Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Krishnan, K. R. R. Articles by Rogers, S. Search for Related Content PubMed Citation Articles by Krishnan, K. R. R. Articles by Rogers, S. Alzheimer's Disease Other Somatic Therapy Molecular Biology MRI MRS

Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease

OBJECTIVE: The authors examined the effect of the acetylcholinesterase inhibitor donepezil on magnetic resonance markers of neurodegeneration in Alzheimer’s disease. METHOD: In this randomized, double-blind, placebo-controlled pilot study, 67 patients with mild to moderate Alzheimer’s disease received 24 weeks of treatment with donepezil (5 mg/day for the first 28 days and 10 mg/day thereafter) or placebo. Patients were reevaluated at 6-week intervals to measure change from baseline in several outcome measures, including right, left, and total hippocampal volumes, measured with magnetic resonance imaging; brain concentrations of N-acetylaspartate, measured with proton magnetic resonance spectroscopy; and cognition, assessed with the Alzheimer’s Disease Assessment Scale cognitive subscale. RESULTS: At some interim assessments, mean normalized measures of N-acetylaspartate concentration tended to be higher in the donepezil-treated patients than in the patients who received placebo, but these differences were not significant at endpoint. At endpoint, the donepezil-treated patients had significantly smaller mean decreases in total and right hippocampal volumes and a smaller, nearly significant mean decrease in left hippocampal volume, compared with the placebo-treated patients. Mean Alzheimer’s Disease Assessment Scale cognitive subscale scores were improved after treatment with donepezil, relative to placebo, at weeks 6, 12, 18, and 24. CONCLUSIONS: These preliminary results suggest that donepezil may have a potentially protective effect in Alzheimer’s disease. Larger, longer-term confirmatory studies of the medication’s effects are warranted.

This article has been cited by other articles:

				K. Kantarci, D. S. Knopman, D. W. Dickson, J. E. Parisi, J. L. Whitwell, S. D. Weigand, K. A. Josephs, B. F. Boeve, R. C. Petersen, and C. R. Jack Jr Alzheimer Disease: Postmortem Neuropathologic Correlates of Antemortem 1H MR Spectroscopy Metabolite Measurements Radiology, July 1, 2008; 248(1): 210 - 220. [Abstract] [Full Text] [PDF]

				A. Qaseem, V. Snow, J. T. Cross Jr., M. A. Forciea, R. Hopkins Jr., P. Shekelle, A. Adelman, D. Mehr, K. Schellhase, D. Campos-Outcalt, et al. Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians Ann Intern Med, March 4, 2008; 148(5): 370 - 378. [Abstract] [Full Text] [PDF]

				P. Raina, P. Santaguida, A. Ismaila, C. Patterson, D. Cowan, M. Levine, L. Booker, and M. Oremus Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline Ann Intern Med, March 4, 2008; 148(5): 379 - 397. [Abstract] [Full Text] [PDF]

				K KANTARCI 1H Magnetic resonance spectroscopy in dementia Br. J. Radiol., December 1, 2007; 80(Special_Issue_2): S146 - S152. [Abstract] [Full Text] [PDF]

				F. Jessen, F. Traeber, K. Freymann, W. Maier, H. H. Schild, and W. Block Treatment monitoring and response prediction with proton MR spectroscopy in AD Neurology, August 8, 2006; 67(3): 528 - 530. [Abstract] [Full Text] [PDF]

				J. L. Cummings Searching for Methods to Detect, Prevent, and Treat Alzheimer's Disease Am J Psychiatry, April 1, 2005; 162(4): 645 - 647. [Full Text] [PDF]

				M. Hashimoto, H. Kazui, K. Matsumoto, Y. Nakano, M. Yasuda, and E. Mori Does Donepezil Treatment Slow the Progression of Hippocampal Atrophy in Patients With Alzheimer's Disease? Am J Psychiatry, April 1, 2005; 162(4): 676 - 682. [Abstract] [Full Text] [PDF]

				B. Seltzer, P. Zolnouni, M. Nunez, R. Goldman, D. Kumar, J. Ieni, S. Richardson, and for the Donepezil "402" Study Group Efficacy of Donepezil in Early-Stage Alzheimer Disease: A Randomized Placebo-Controlled Trial Arch Neurol, December 1, 2004; 61(12): 1852 - 1856. [Abstract] [Full Text] [PDF]

				K. Kantarci, R. C. Petersen, B. F. Boeve, D. S. Knopman, D. F. Tang-Wai, P. C. O'Brien, S. D. Weigand, S. D. Edland, G. E. Smith, R. J. Ivnik, et al. 1H MR spectroscopy in common dementias Neurology, October 26, 2004; 63(8): 1393 - 1398. [Abstract] [Full Text] [PDF]

				J. Rosack Med Check Psychiatr News, November 7, 2003; 38(21): 29 - 29. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us